


Status: Currently Official on 15-Feb-2025
Official Date: Official as of 01-Feb-2023
Document Type: USP Monographs
DocId: GUID-D87B545A-5214-4F61-BB7E-63CAEDF3B87E_6_en-US
DOI: https://doi.org/10.31003/USPNF_M49760_06_01
DOI Ref: 83rwc

© 2025 USPC
Do not distribute

Metaraminol Bitartrate



$C_9H_{13}NO_2 \cdot C_4H_6O_6$ 317.29
Benzenemethanol, α -(1-aminoethyl)-3-hydroxy-, [R-(R*,S*)]-, [R-(R*,R*)]-2,3-dihydroxybutanedioate (1:1) (salt);
(-)- α -(1-Aminoethyl)-*m*-hydroxybenzyl alcohol tartrate (1:1) (salt) CAS RN®: 33402-03-8; UNII: ZC4202M9P3.

DEFINITION

Metaraminol Bitartrate contains NLT 98.0% and NMT 102.0% of metaraminol bitartrate ($C_9H_{13}NO_2 \cdot C_4H_6O_6$), calculated on the dried basis.

IDENTIFICATION

- A. [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), [Infrared Spectroscopy](#): 197A or 197K
- B. The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

PROCEDURE

Solution A: Dissolve 3.24 g of anhydrous [octanesulphonic acid sodium salt](#) in 1 L of water.
Solution B: [Acetonitrile](#) and [water](#) (90:10)
Diluent: [Acetonitrile](#) and [water](#) (20:80)
Mobile phase: See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	80	20
5	80	20
20	5	95
30	5	95
30.1	80	20
40	80	20

Standard solution: 0.75 mg/mL of [USP Metaraminol Bitartrate RS](#) in *Diluent*

Sample solution: 0.75 mg/mL of Metaraminol Bitartrate in *Diluent*

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC
Detector: UV 210 nm
Column: 4.6-mm × 15-cm; 3- μ m packing L1
Column temperature: 35°
Flow rate: 1 mL/min
Injection volume: 10 μ L
System suitability
Sample: *Standard solution*
Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 0.73%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of metaraminol bitartrate ($C_9H_{13}NO_2 \cdot C_4H_6O_6$) in the portion of Metaraminol Bitartrate taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of metaraminol from the *Sample solution*

r_S = peak response of metaraminol from the *Standard solution*

C_S = concentration of [USP Metaraminol Bitartrate RS](#) in the *Standard solution* (mg/mL)

C_U = concentration of Metaraminol Bitartrate in the *Sample solution* (mg/mL)

Acceptance criteria: 98.0%–102.0% on the dried basis

IMPURITIES

• [RESIDUE ON IGNITION \(281\)](#): NMT 0.1%

• **ORGANIC IMPURITIES**

Solution A, Solution B, Diluent, Mobile phase, Standard solution, Sample solution, and Chromatographic system: Proceed as directed in the Assay.

Peak identification solution: 0.1 mg/mL each of [USP Metaraminol Bitartrate RS](#), [USP Metaraminol Related Compound A RS](#), and [USP Metaraminol Related Compound B RS](#) in *Diluent*

Sensitivity solution: 0.76 µg/mL of [USP Metaraminol Bitartrate RS](#) in *Diluent* from the *Standard solution*

System suitability

Samples: *Standard solution* and *Sensitivity solution*

Suitability requirements

Tailing factor: NMT 2.0, *Standard solution*

Signal-to-noise ratio: NLT 15, *Sensitivity solution*

Analysis

Sample: *Sample solution*

Calculate the percentage of metaraminol related compound A and any unspecified impurity in the portion of Metaraminol Bitartrate taken:

$$\text{Result} = (r_U/r_T) \times 100$$

r_U = peak response of metaraminol related compound A or any unspecified impurity from the *Sample solution*

r_T = sum of all the peak responses from the *Sample solution*

Acceptance criteria: See [Table 2](#). Disregard peaks due to tartaric acid and metaraminol related compound B.

Table 2

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Tartaric acid	0.13 and 0.14	—
Metaraminol	1.00	—
Metaraminol related compound B	1.52	—
Metaraminol related compound A	1.82	0.15
Any unspecified impurity	—	0.10
Total impurities	—	1.0

• LIMIT OF METARAMINOL RELATED COMPOUND B

Solution A: Dissolve 1.88 g of anhydrous [1-hexane sulfonic acid sodium salt](#) and 1.36 g of [monobasic potassium phosphate](#) in 1 L of [water](#). Adjust with dilute [phosphoric acid](#) to a pH of 2.6.

Solution B: [Acetonitrile](#) and [water](#) (85:15)

Diluent: [Acetonitrile](#) and [water](#) (20:80)

Mobile phase: See [Table 3](#).

Table 3

Time (min)	Solution A (%)	Solution B (%)
0	70	30
5	70	30
10	55	45
15	50	50
18	50	50
21	10	90
30	10	90
31	70	30
35	70	30

Standard solution: 0.0012 mg/mL of [USP Metaraminol Related Compound B RS](#) in *Diluent*

Sample solution: 0.75 mg/mL of Metaraminol Bitartrate in *Diluent*

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 210 nm

Column: 4.6-mm × 25-cm; 5-μm packing L1

Column temperature: 35°

Flow rate: 1 mL/min

Injection volume: 10 μL

System suitability

Sample: *Standard solution*

Suitability requirements

Relative standard deviation: NMT 15.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of metaraminol related compound B in the portion of Metaraminol Bitartrate taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of metaraminol related compound B from the *Sample solution*

r_S = peak response of metaraminol related compound B from the *Standard solution*

C_S = concentration of [USP Metaraminol Related Compound B RS](#) in the *Standard solution* (mg/mL)

C_U = concentration of Metaraminol Bitartrate in the *Sample solution* (mg/mL)

Acceptance criteria: NMT 0.15%

• **ENANTIOMERIC PURITY**

Mobile phase: Heptane, methanol, isopropyl alcohol, and methane sulfonic acid (80:10:10:0.2)

Metaraminol enantiomer stock solution: 0.05 mg/mL of [USP Metaraminol Enantiomer RS](#) in *Mobile phase*

System suitability solution: 1 mg/mL of [USP Metaraminol Bitartrate RS](#) and 0.005 mg/mL of [USP Metaraminol Enantiomer RS](#) from *Metaraminol enantiomer stock solution* in *Mobile phase*

Sensitivity solution: 1 μg/mL of [USP Metaraminol Bitartrate RS](#) in *Mobile phase*

Sample solution: 1 mg/mL of Metaraminol Bitartrate in *Mobile phase*

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 220 nm

Column: 4.6-mm × 25-cm; 3-μm packing [L51](#)

Column temperature: 40°

Flow rate: 0.5 mL/min

Injection volume: 10 μL

Run time: NLT 3 times the retention time of metaraminol

System suitability

Samples: *System suitability solution* and *Sensitivity solution*

[NOTE—The relative retention times for metaraminol and the metaraminol enantiomer are about 1.0 and 1.1, respectively.]

Suitability requirements

Resolution: NLT 1.5 between the metaraminol and the metaraminol enantiomer peaks, *System suitability solution*

Signal-to-noise ratio: NLT 15, *Sensitivity solution*

Analysis

Sample: *Sample solution*

Calculate the percentage of metaraminol enantiomer in the portion of Metaraminol Bitartrate taken:

$$\text{Result} = (r_U/r_T) \times 100$$

r_U = peak response of metaraminol enantiomer from the *Sample solution*

r_T = sum of all the peak responses from the *Sample solution*

Acceptance criteria: NMT 0.15%

SPECIFIC TESTS

Change to read:

• CONTENT OF TARTARIC ACID

Sample solution: To 0.1 g of Metaraminol Bitartrate, add 60 mL of [dimethylformamide](#), and sonicate for 2 min.

Titrimetric system

Mode: Direct titration

Titrant: [0.1 N tetrabutylammonium hydroxide VS](#)

Endpoint detection: Potentiometric

Blank: [Dimethylformamide](#)

Analysis: Titrate with *Titrant* potentiometrically using a suitable electrode. [NOTE—A suitable electrode may be 6.0229.100, 0–14 pH, 70°, lithium chloride saturated in alcohol.] Perform a blank determination, and make any necessary correction.

Calculate the percentage of tartaric acid in the portion of Metaraminol Bitartrate taken:

$$\text{Result} = \{[(V_S - V_B) \times N \times F] / (2 \times W)\} \times 100 \quad (\text{ERR 1-Feb-2023})$$

V_S = *Titrant* volume consumed by the *Sample solution* (mL)

V_B = *Titrant* volume consumed by the *Blank* (mL)

N = actual normality of the *Titrant* (mEq/mL)

F = equivalency factor, 150.09 mg/mEq

W = weight of Metaraminol Bitartrate in the *Sample solution* (mg)

Acceptance criteria: 44.9%–49.7% on the dried basis

• [pH \(791\)](#)

Sample solution: 50 mg/mL of Metaraminol Bitartrate in water

Acceptance criteria: 3.2–3.5

• [Loss on Drying \(731\)](#)

Analysis: Dry at 105° for 2 h.

Acceptance criteria: NMT 1.0%

ADDITIONAL REQUIREMENTS

• **PACKAGING AND STORAGE:** Preserve in well-closed containers. Store at controlled room temperature.

Change to read:

• [USP REFERENCE STANDARDS \(11\)](#)

[USP Metaraminol Bitartrate RS](#)

[USP Metaraminol Related Compound A RS](#)

(*E*)-1-[3-(Benzyloxy)phenyl]-2-(hydroxyimino)propan-1-one.

$\text{C}_{16}\text{H}_{15}\text{NO}_3$ 269.30

[USP Metaraminol Related Compound B RS](#)

2-Amino-1-[3-(benzyloxy)phenyl]propan-1-ol.
C₁₆H₁₉NO₂ 257.33

[USP Metaraminol Enantiomer RS](#)

3-[(1S,2R)-2-Amino-1-hydroxypropyl]phenol ▲D-tartrate▲ (ERR 1-Feb-2023) ·
C₉H₁₃NO₂▲ · C₄H₆O₆▲ (ERR 1-Feb-2023) ▲317.29▲ (ERR 1-Feb-2023)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
METARAMINOL BITARTRATE	Documentary Standards Support	SM22020 Small Molecules 2

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 44(1)

Current DocID: GUID-D87B545A-5214-4F61-BB7E-63CAEDF3B87E_6_en-US

DOI: https://doi.org/10.31003/USPNF_M49760_06_01

DOI ref: [83rwc](#)

OFFICIAL